• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估尿路致病性大肠杆菌分离株中FyuA铁受体作为抗尿路感染疫苗靶点的流行率、免疫原性和功效。

Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.

作者信息

Habibi Mehri, Asadi Karam Mohammad Reza, Bouzari Saeid

机构信息

Department of Molecular Biology, Pasteur Institute of Iran, Pasteur Ave., Tehran 13164, Iran.

Department of Molecular Biology, Pasteur Institute of Iran, Pasteur Ave., Tehran 13164, Iran.

出版信息

Microb Pathog. 2017 Sep;110:477-483. doi: 10.1016/j.micpath.2017.07.037. Epub 2017 Jul 25.

DOI:10.1016/j.micpath.2017.07.037
PMID:28754265
Abstract

Uropathogenic Escherichia coli (UPEC) are among the most prevalent agents of urinary tract infections (UTIs). Antibiotic resistance reaches the need for alternative treatment approaches such as vaccination against UTIs. There is no ideal vaccine against UTIs, thus there is a need to evaluate different targets of uropathogens against UTIs. Ferric scavenger receptor FyuA in UPEC has the properties of an ideal vaccine candidate against UTIs. In the present study, the prevalence of FyuA among UPEC isolates, its immunogenicity with and without alum adjuvant, and its efficacy against experimental UTI were assessed. Totally, fyuA gene was present in 77% of the UPEC isolates tested. Alignments of FyuA exhibited a high degree of conservation among different submitted UPEC isolates in GenBank. The bioinformatics studies showed the high confidence value and stability of the FyuA structure. SDS-PAGE and Western blot confirmed the purification of FyuA with high yield by nickel resins. Mice vaccinated subcutaneously with the FyuA induced a significantly higher humoral response (total IgG, IgG1 and IgG2a) than control mice that alum enhanced these responses. The FuyA alone showed the ability to reduce the colonization of UPEC in bladder and kidney of mice as compared to the control group. But the addition of alum to FyuA increased the protection level against UPEC in these organs. Since, FyuA induced significant IgG1 (Th2) and IgG2a (Th1) responses and protected the mice against experimental UTI, it could be a promising target against UPEC infections.

摘要

尿路致病性大肠杆菌(UPEC)是尿路感染(UTIs)最常见的病原体之一。抗生素耐药性使得需要诸如针对尿路感染的疫苗接种等替代治疗方法。目前尚无理想的抗尿路感染疫苗,因此有必要评估尿路病原体针对尿路感染的不同靶点。UPEC中的铁清除受体FyuA具有成为抗尿路感染理想疫苗候选物的特性。在本研究中,评估了FyuA在UPEC分离株中的流行情况、其在有无明矾佐剂情况下的免疫原性以及其对实验性尿路感染的疗效。总共,在所测试的UPEC分离株中,77%存在fyuA基因。FyuA的比对显示在GenBank中不同提交的UPEC分离株之间具有高度保守性。生物信息学研究表明FyuA结构具有高置信度值和稳定性。SDS-PAGE和蛋白质印迹证实通过镍树脂可高产率纯化FyuA。皮下接种FyuA的小鼠诱导的体液反应(总IgG、IgG1和IgG2a)明显高于对照组小鼠,明矾可增强这些反应。与对照组相比,单独的FuyA显示出降低UPEC在小鼠膀胱和肾脏中定植的能力。但在FyuA中添加明矾可提高在这些器官中针对UPEC的保护水平。由于FyuA诱导了显著的IgG1(Th2)和IgG2a(Th1)反应并保护小鼠免受实验性尿路感染,它可能是对抗UPEC感染的一个有前景的靶点。

相似文献

1
Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.评估尿路致病性大肠杆菌分离株中FyuA铁受体作为抗尿路感染疫苗靶点的流行率、免疫原性和功效。
Microb Pathog. 2017 Sep;110:477-483. doi: 10.1016/j.micpath.2017.07.037. Epub 2017 Jul 25.
2
Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.重组 FimH 与鞭毛蛋白融合疫苗增强小鼠尿路感染的细胞和体液免疫。
Vaccine. 2013 Feb 6;31(8):1210-6. doi: 10.1016/j.vaccine.2012.12.059. Epub 2013 Jan 7.
3
Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.优化一种预防大肠杆菌尿路感染的实验性疫苗。
mBio. 2020 Apr 28;11(2):e00555-20. doi: 10.1128/mBio.00555-20.
4
Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection.用耶尔森菌外菌素受体 FyuA 进行免疫接种可预防尿路感染小鼠模型中的肾盂肾炎。
Infect Immun. 2013 Sep;81(9):3309-16. doi: 10.1128/IAI.00470-13. Epub 2013 Jun 24.
5
Immunization with recombinant protein Ag43::UpaH with alum and 1,25(OH)2D3 adjuvants significantly protects Balb/C mice against urinary tract infection caused by uropathogenic Escherichia coli.用重组蛋白 Ag43::UpaH 联合明矾和 1,25(OH)2D3 佐剂进行免疫接种,可显著保护 Balb/C 小鼠免受尿路致病性大肠杆菌引起的尿路感染。
Int Immunopharmacol. 2021 Jul;96:107638. doi: 10.1016/j.intimp.2021.107638. Epub 2021 Apr 10.
6
Design of a chimeric protein composed of FimH, FyuA and CNF-1 virulence factors from uropathogenic Escherichia coli and evaluation its biological activity and immunogenicity in vitro and in vivo.设计一种嵌合蛋白,由尿路致病性大肠杆菌的 FimH、FyuA 和 CNF-1 毒力因子组成,并在体外和体内评估其生物学活性和免疫原性。
Microb Pathog. 2023 Jan;174:105920. doi: 10.1016/j.micpath.2022.105920. Epub 2022 Nov 29.
7
Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.在尿路感染小鼠模型中评估MPL及给药途径对源自尿路致病性大肠杆菌和奇异变形杆菌的不同FimH和MrpH制剂的免疫原性和保护作用的影响。
Int Immunopharmacol. 2015 Sep;28(1):70-8. doi: 10.1016/j.intimp.2015.05.027. Epub 2015 May 29.
8
Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.鼻腔内免疫融合蛋白 MrpH·FimH 和 MPL 佐剂可预防由尿路致病性大肠杆菌和奇异变形杆菌引起的尿路感染。
Mol Immunol. 2015 Apr;64(2):285-94. doi: 10.1016/j.molimm.2014.12.008. Epub 2015 Jan 4.
9
Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.尿路感染:尿路致病性大肠杆菌的致病性、抗生素耐药性和有效疫苗的开发。
Mol Immunol. 2019 Apr;108:56-67. doi: 10.1016/j.molimm.2019.02.007. Epub 2019 Feb 18.
10
Local induction of bladder Th1 responses to combat urinary tract infections.局部诱导膀胱 Th1 反应以对抗尿路感染。
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10). doi: 10.1073/pnas.2026461118.

引用本文的文献

1
Immunoinformatics investigation on pathogenic Escherichia coli proteome to develop an epitope-based peptide vaccine candidate.对致病性大肠杆菌蛋白质组进行免疫信息学研究,以开发一种基于表位的候选肽疫苗。
Mol Divers. 2024 Nov 8. doi: 10.1007/s11030-024-11034-0.
2
Vaccines against extraintestinal pathogenic (ExPEC): progress and challenges.针对肠外致病性大肠杆菌(ExPEC)的疫苗:进展与挑战。
Gut Microbes. 2024 Jan-Dec;16(1):2359691. doi: 10.1080/19490976.2024.2359691. Epub 2024 Jun 2.
3
Progress toward a vaccine for extraintestinal pathogenic (ExPEC) II: efficacy of a toxin-autotransporter dual antigen approach.
针对肠外致病性大肠杆菌(ExPEC)疫苗的研究进展 II:毒素-自转运体双抗原方法的疗效。
Infect Immun. 2024 May 7;92(5):e0044023. doi: 10.1128/iai.00440-23. Epub 2024 Apr 9.
4
Urinary Tract Infections Caused by Uropathogenic : Mechanisms of Infection and Treatment Options.尿路感染的病原体:感染机制和治疗选择。
Int J Mol Sci. 2023 Jun 23;24(13):10537. doi: 10.3390/ijms241310537.
5
The Diversity of Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen.针对这种多面性细菌病原体的致病型多样性及疫苗接种策略
Microorganisms. 2023 Jan 30;11(2):344. doi: 10.3390/microorganisms11020344.
6
Immunomodulation therapy offers new molecular strategies to treat UTI.免疫调节疗法为治疗尿路感染提供了新的分子策略。
Nat Rev Urol. 2022 Jul;19(7):419-437. doi: 10.1038/s41585-022-00602-4. Epub 2022 Jun 22.
7
Designing of an Epitope-Based Vaccine Against Common Pathotypes.基于表位的针对常见致病型疫苗的设计
Front Med (Lausanne). 2022 Mar 4;9:829467. doi: 10.3389/fmed.2022.829467. eCollection 2022.
8
"Omics" Technologies - What Have They Told Us About Uropathogenic Fitness and Virulence During Urinary Tract Infection?“组学”技术——它们在尿路感染期间告诉了我们关于尿路病原体适应性和毒力的什么?
Front Cell Infect Microbiol. 2022 Feb 14;12:824039. doi: 10.3389/fcimb.2022.824039. eCollection 2022.
9
Relationship between Escherichia coli virulence factors, notably kpsMTII, and symptoms of clinical metritis and endometritis in dairy cows.大肠杆菌毒力因子(特别是 kpsMTII)与奶牛临床子宫炎和子宫内膜炎症状之间的关系。
J Vet Med Sci. 2022 Mar 15;84(3):420-428. doi: 10.1292/jvms.21-0586. Epub 2022 Jan 27.
10
Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs.复发性尿路感染:揭示单纯性 rUTI 复杂环境的奥秘。
Front Cell Infect Microbiol. 2021 Jul 22;11:562525. doi: 10.3389/fcimb.2021.562525. eCollection 2021.